UNASSIGNED: @entity30854 ( @entity30854 ) is used to treat @entity2210 and @entity1661 in @entity1 . However, reports revealed that @entity6327 , the most important active constituent of @entity30854 , possesses potential @entity137 . This study was designed to investigate the optimum @entity6327 content in @entity30854 , using the "target constituent removal combined with bioactivity assay" strategy. Based on PTLC method, we prepared @entity30854 lacking all @entity6327 (WAC-100R) and a series of different ratios of @entity6327 -removed @entity30854 samples (WAC-Rx). @entity98 and acute @entity137 assays indicated that decreasing content by 50% decreased @entity30854 @entity137 significantly. Animal results revealed @entity6327 contents over 50% could guarantee the beneficial effects of @entity30854 on gastrointestinal tract. Additionally, decreasing @entity6327 content in @entity30854 by 50% decreased its pro-apoptotic effects significantly. Furthermore, decreasing 50% @entity6327 content in @entity30854 down-regulated the expressions of Cleaved-Caspase-3, @entity1178 , @entity1639 , @entity2247 , @entity1421 , and @entity1192 . Thus, our results revealed that @entity30854 with 50% @entity6327 content (WAC-50R) has similar beneficial effects on the gastrointestinal tract to @entity30854 , whereas its @entity137 was decreased significantly. Collectively, our study suggested that the strategy of "target constituent removal combined with bioactivity assay" is a promising method to identify the optimum @entity6327 content in @entity30854 , which is approximately 0.12%.

Using the "target constituent removal combined with bioactivity assay" strategy to investigate the optimum XXXX content in charred areca nut.

@entity1 :: ('9606', 'Species') :: ['children'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity30854 :: ('MESH:C566815', 'Disease') :: ['Charred areca nut', 'CAN'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2'] @entity1661 :: ('MESH:D000008', 'Disease') :: ['abdominal distension'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity1178 :: ('3725', 'Gene') :: ['c-jun'] @entity1639 :: ('2353', 'Gene') :: ['c-fos'] @entity1192 :: ('3552', 'Gene') :: ['IL-1a'] @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia'] @entity2247 :: ('4513', 'Gene') :: ['COX-2'] @entity6327 :: ('MESH:D001115', 'Chemical') :: ['arecoline']
@entity6327 :: (MESH:D001115,Chemical) :: ['arecoline']
